Furthermore, studies involving RA patients without diabetes could elucidate whether IL-1 antagonism may have an impact on the prevention of prediabetes and T2D in selected at-risk groups (e.g., patients with RA and obesity and/or metabolic syndrome, or patients with RA on high-dose corticosteroid therapy). This evidence concerns the gene IL1B and type 2 diabetes mellitus.